Proscia, a provider of digital and computational pathology solutions, announced that Altasciences, a contract research organization (CRO), has chosen Proscia’s Concentriq for Research to help its sponsors advance life-saving therapeutics.

The CRO will deploy Proscia’s software platform to help advance faster, more complete preclinical development decisions.

“Our decision to adopt digital pathology and chart our course with Proscia strongly reflects Altasciences’ guiding focus on ensuring our sponsors’ success,” said Wendell Davis, vice president of Pathology. “Concentriq for Research is the only platform that offers the robust feature set and scalability essential to meeting the evolving needs of our scientists and the biopharmaceutical organizations that we serve.”

Altasciences will initially deploy Concentriq for Research to unify massive volumes of study data and streamline collaboration among internal and external stakeholders, enabling its scientists to draw faster, more complete conclusions and increasingly work as an extension of sponsors’ teams.

The CRO also plans to draw on the platform’s newly expanded capabilities for GLP compliant studies as well as leverage its interoperability to unlock new insights with artificial intelligence (AI).

“Altasciences is an incredibly forward-thinking contract research organization that shares our commitment to innovation,” said David West, Proscia’s CEO. “We are humbled that its team has selected Concentriq for Research to drive its digital pathology operations and play a key role in helping its sponsors accelerate the introduction of life-saving drugs.”